PerspectiveCancer Immunotherapy

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

See allHide authors and affiliations

Science Translational Medicine  28 Mar 2012:
Vol. 4, Issue 127, pp. 127ps8
DOI: 10.1126/scitranslmed.3003634

You are currently viewing the abstract.

View Full Text


Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

View Full Text